Samsung Shares Drop as Labor Union Confirms Planned Strike 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
Stellantis CEO Antonio Filosa to Reveal Turnaround Strategy Focused on U.S. Sales and China Partnerships 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Google, Blackstone Launch $5B AI Cloud Venture to Challenge Nvidia and CoreWeave 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Mistral AI Acquires Emmi AI to Expand Industrial AI Solutions in Europe 
Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
 & Lead Plaintiff Deadline: October 31, 2016 - EconoTimes)
NEW YORK, Sept. 19, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against American Renal Associates Holdings, Inc. (“American Renal Associates” or the “Company”) (NYSE:ARA) and certain of its officers. The class action is on behalf of a class consisting of all persons or entities who purchased American Renal Associates securities: (1) pursuant and/or traceable to American Renal’s Initial Public Offering on or about April 21, 2016 (the “IPO”); and/or (2) from April 21, 2016 through August 18, 2016, inclusive (the “Class Period”).
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) American Renal was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act plans to obtain greater reimbursement for American Renal’s dialysis services; (2) the foregoing scheme was in violation of federal and state laws; and (3) as a result, American Renal’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/ara or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in American Renal Associates you have until October 31, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
